Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Beam Therapeutics Presents Data Highlighting Robust Manufacturing Process For BEAM-101 At EHA 2024 Hybrid Congress June 13-16, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated
byBenzinga Newsdesk
May 14, 2024
1 minute read
Total
0
Shares
0
0
0
0
0
0

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated manufacturing process for BEAM-101, as deployed in the BEACON Phase 1/2 clinical trial, in a poster presentation at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Madrid, Spain on June 13-16, 2024.

 

Abstract details are listed below and available online on the EHA meeting library website.

Title: Robust autologous CD34+ HSPC manufacturing with a closed and automated process optimized for patients with sickle cell disease

Poster Session Date and Time: Friday, June 14, 2024, 6:00 p.m. CEST

Abstract: P1479

Presenting Author: Paul Kopesky, Ph.D., vice president, process development at Beam Therapeutics

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Regeneron, Sanofi Announced Earlier , Dupixent Recommended For Expanded EU Approval By The CHMP To Treat Children As Young As Six Months Old With Severe Atopic Dermatitis

By Charles Gross
January 27, 5:46 AM
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent® (dupilumab), recommending expanded approval in the European Union (EU) to treat severe atopic dermatitis in children 6 months to 5 years old who are candidates for systemic therapy.

REGN